Combined Treatment With Sulpiride and Paroxetine for Accelerated Response in Patients With Major Depressive Disorder
Combined Treatment With Sulpiride and Paroxetine for Accelerated Response in Patients With Major Depressive Disorder
复制标题
舒必利和帕罗西汀联合治疗可加速重度抑郁症患者的缓解
DOI：
--
复制
发表时间：
2005
影响因子：
2.9
通讯作者：
H. Kashima
中科院分区：
文献类型：
--
作者：
H. Uchida;H. Takeuchi;Takefumi Suzuki;K. Nomura;Koichiro Watanabe;H. Kashima
摘要：虽然5 -羟色胺再摄取抑制剂被推荐作为治疗重度抑郁症的一线药物，但延迟起效是一个问题，需要更快有效的治疗。舒必利是一种多巴胺介导的药物，有报道称其抗抑郁疗效更快，我们检查了辅助舒必利与帕罗西汀（PAX）联合治疗的疗效，与单独使用PAX相比，以阐明联合治疗是否能更快地发挥作用。41名重度抑郁症患者参加了这项为期12周的开放标签试验，并被随机分配到PAX （10-40 mg/d）或PAX （10-40 mg/d）加舒必利（100 mg/d）组。评估包括蒙哥马利-阿斯伯格抑郁评定量表、17项汉密尔顿抑郁评定量表和Zung抑郁自评量表，并对安全性进行监测。33名患者完成了这项研究。PAX +舒必利治疗组和PAX治疗组的Montgomery-Asberg抑郁评定量表总分平均分别从34.4降至5.6分和32.2降至10.4分（P < 0.001）。在蒙哥马利-阿斯伯格抑郁评定量表、汉密尔顿抑郁评定量表和Zung抑郁自评量表总分从第1周到研究终点的变化方面，联合治疗组的结果显著优于对照组（P < 0.05）。联合治疗和单药治疗的应答者中位应答时间分别为2周和6周。两种治疗的耐受性都很好，除了联合治疗组催乳素升高外，在安全性措施上没有临床显著差异。联合治疗可能是一种安全有效的加速抗抑郁反应的策略。
Abstract: Although serotonin reuptake inhibitors are recommended as first-line agents for major depressive disorder, delayed onset of action is problematic, and faster effective treatment is needed. Sulpiride, a dopamine-mediated agent, has been reported to show faster antidepressant efficacy, and we examined the efficacy of adjunctive sulpiride in combination with paroxetine (PAX), compared with PAX alone, to clarify whether the combined treatment exerts faster effect. Forty-one major depressive disorder patients were enrolled in this 12-week open-label trial and were randomly assigned to a PAX (10-40 mg/d) or a PAX (10-40 mg/d) plus sulpiride (100 mg/d) group. Assessments included the Montgomery-Asberg Depression Rating Scale, the 17-item Hamilton Rating Scale for Depression, and the Zung Self-rating Depression Scale on an intent-to-treat basis, and safety was also monitored. Thirty-three patients completed the study. Both PAX + sulpiride and PAX treatments showed a mean reduction in the total Montgomery-Asberg Depression Rating Scale score of 34.4 to 5.6 and 32.2 to 10.4, respectively (P < 0.001). The combined treatment group had a significantly superior outcome in terms of the change in the total Montgomery-Asberg Depression Rating Scale, Hamilton Rating Scale for Depression, and Zung Self-rating Depression Scale scores between week 1 and the study end point (P < 0.05). Median times to response among responders alone for the combined treatment and monotherapy were 2 and 6 weeks, respectively. Both treatments were well tolerated, with no clinically significant differences in safety measures except for an elevation of prolactin in the combined treatment group. The combination treatment may be a safe and effective strategy for accelerating antidepressant response.
影响因子：
17.7
作者：
Goldberg, JF;Burdick, KE;Endick, CJ
通讯作者：
Endick, CJ
口服 S-腺苷甲硫氨酸治疗抑郁症：一项随机、双盲、安慰剂对照试验。
DOI：
10.1176/ajp.147.5.591
发表时间：
1990
期刊：
The American journal of psychiatry
影响因子：
--
作者：
Kagan,BL;Sultzer,DL;Rosenlicht,N;Gerner,RH
通讯作者：
Gerner,RH
影响因子：
5.3
作者：
Crismon, ML;Trivedi, M;Thase, ME
通讯作者：
Thase, ME